Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sun Yat-sen University
With
First Affiliated Hospital, Sun Yat-Sen University
Second Affiliated Hospital, Sun Yat-Sen University
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients between 18 and 75 years of age.
Present with histologically proven or cytological diagnosis of non-Squamous NSCLC Stage IIIB or IV as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer, that is not amenable to curative therapy,such as surgery or radiotherapy and so on.
No prior systemic chemotherapy or targeted therapy for lung cancer before screening.
Confirmed activating mutation of EGFR-ie, an exon 19 deletion or an exon 21 L858R point mutation.
Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1.
Adequate organ function.
Prior radiation therapy allowed to \<25% of the bone marrow . Prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks before study enrollment. Patients must have recovered from the acute toxic effects of the treatment prior to study enrollment.
Signed informed consent document on file.
Estimated life expectancy of ≥12 weeks.
Patient compliance and geographic proximity that allow adequate follow up.
You may not be if
Known severe hypersensitivity to erlotinib.
Patients with uncontrolled brain metastasis.
Pleural effusion or pericardiac effusion that cannot be controlled by drainage or other procedures.
Inability to comply with protocol or study procedures.
A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.
Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
Interstitial pneumonia.
Clareo Health | Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
